Pheochromocytoma-paraganglioma type 5 syndrome associated with mutation in the succinate dehydrogenase type A complex (SDHA), a case report
DOI:
https://doi.org/10.17533/udea.iatreia.187Keywords:
Pheochromocytoma, PC12 cells, paraganglioma, Succinate Dehydrogenase, Neurosecretory SystemsAbstract
Pheochromocytomas and paragangliomas are rare neuroendocrine neoplasms that can produce catecholamines, with an incidence of less than one case per million inhabitants. They are histologically benign and minimally different from their malignant counterparts. The most common mutation is in the succinate dehydrogenase (SDH) complex pathway, and one of the least reported is the SDH subunit A (SDHA) mutation. A case of a patient with pheochromocytoma and paraganglioma, associated with mutation in SDHA, its behavior and good clinical response to surgical management and active surveillance is described.
Downloads
References
(1) Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med [Internet]. 2019 Ago;381(6):552-65. DOI 10.1056/NEJMra1806651.
(2) Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med [Internet]. 2018;51:68-73. DOI 10.1016/j.ejim.2018.01.015.
(3) Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet [Internet]. 2002;39(9):617-22. DOI 10.1136/jmg.39.9.617.
(4) Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab [Internet]. 2014;99(6):1915-42. DOI 10.1210/jc.2014-1498.
(5) Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5. Endocr Relat Cancer [Internet]. 2015;22(4):T91-103. DOI 10.1530/ERC-15-0268.
(6) Toledo R, Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. F1000Research [Internet]. 2018;7:1148. DOI 10.12688/f1000research.13995.1.
(7) Gomez AM, Soares DC, Costa AAB, Pereira DP, Achatz MI, Formiga MN. Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance. Arch Endocrinol Metab [Internet]. 2019;63(4):369-375.DOI 10.20945/2359-3997000000145.
(8) Liu Z, Ma J, Jimenez C, Zhang M. Pheochromocytoma: A Clinicopathologic and Molecular Study of 390 Cases From a Single Center. Am J Surg Pathol [Internet]. 2021;45(9):1155-65. DOI 10.1097/PAS.0000000000001768.
(9) Welander J, Garvin S, Bohnmark R, Isaksson L, Wiseman RW, Soderkvist P, et al. Germline SDHA Mutation Detected by Next-Generation Sequencing in a Young Index Patient With Large Paraganglioma. J Clin Endocrinol Metab [Internet]. 2013;98(8):E1379-80. DOI 10.1210/jc.2013-1963.
(10) Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, et al. SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. J Clin Endocrinol Metab [Internet]. 2011;96(9):E1472-6. DOI 10.1210/jc.2011-1043.
(11) Tufton N, Ghelani R, Srirangalingam U, Kumar AV, Drake WM, Iacovazzo D, et al. SDHA mutated paragangliomas may be at high risk of metastasis. Endocr Relat Cancer [Internet]. 2017;24(7):L43-9. DOI 10.1530/ERC-17-0030.
(12) Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer [Internet]. 2014;14(2):108-19. DOI 10.1038/nrc3648.
(13) Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1) Eur J Cancer. 2009;45:228–47. DOI 10.1016/j.ejca.2008.10.026.
(14) Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas [Internet]. 2013;42(4):557-77. DOI 10.1097/MPA.0b013e31828e34a4.
(15) Kunst HPM, Rutten MH, de Monnink JP, Hoefsloot LH, Timmers HJLM, Marres HAM, et al. SDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma. Clin Cancer Res [Internet]. 2011;17(2):247-54. DOI 10.1158/1078-0432.CCR-10-0420.
(16) Nolting, Ullrich, Pietzsch, Ziegler, Eisenhofer, Grossman, et al. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers [Internet]. 2019;11(10):1505. DOI 10.3390/cancers11101505.
(17) Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA , TMEM127 , MAX , and SDHAF2 for Gene-Informed Prevention. JAMA Oncol [Internet]. 2017;3(9):1204. DOI 10.1001/jamaoncol.2017.0223.
(18) Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435-44. DOI: 10.1038/s41574-021-00492-3.
(19) Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Front Oncol [Internet]. 2019;9:53. DOI 10.3389/fonc.2019.00053.
(20) van der Tuin K, Mensenkamp AR, Tops CMJ, Corssmit EPM, Dinjens WN, van de Horst-Schrivers AN, et al. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. J Clin Endocrinol Metab [Internet]. 2018;103(2):438-45. DOI 10.1210/jc.2017-01762.
(21) Jimenez C. Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. Front Endocrinol (Lausanne) [Internet]. 2018;9:277. DOI 10.3389/fendo.2018.00277.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
